← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Revel Pharmaceuticals Inc.
San Francisco, CA
$2,942,757
Total funding
6
Grants
Funding over time
peak $1.7M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$2,942,757 · 6
By mechanism
R43$1,578,595 · 5
R44$1,364,162 · 1
Investigators at Revel Pharmaceuticals Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts$1,364,162
R44 · FY2025 · AG
Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic retinopathy$358,065
R43 · FY2025 · EY
An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts$346,755
R43 · FY2024 · GM
Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease$324,015
R43 · FY2024 · DK
Development of enzymatic tools for rapid measurement of Advanced Glycation End Product-protein adducts$277,623
R43 · FY2023 · AG
An enzyme-based assay for the detection of acetaldehyde-protein adducts$272,137
R43 · FY2023 · AA